Oxford BioMedica
Discover Realise


Our vision: Oxford BioMedica is a leading company in gene and cell therapy with an integrated platform of exclusive and pioneering technologies to design, develop and bioprocess unique gene-based medicines.

Our in-house capabilities span research, clinical development, bioprocessing and regulatory affairs. Our staff numbers 231 (as at 31 December 2015), are mainly based in our laboratories and headquarters at Windrush Court, Cowley, Oxford in addition we have teams based at our state-of-the-art GMP bioprocessing facilities Yarnton and in Cowley, Oxford.

Our goal is to help facilitate access to life changing treatments for patients with a variety of clinical indications, and our success will be reflected in:

the substantial difference we can make as we tackle some of the most challenging issues in health today;

the returns we can achieve for those who have trusted and invested in our potential; and

our own investment in the people whose commitment and dedication make our ambitions more achievable every day
And we are succeeding.

We are entering an enormously exciting phase of growth. We acquired large new premises at Windrush Court in Cowley, opposite our bioprocessing facility, which has completed expansion. Our investment in building bioprocessing capability in-house is enabling both us and our industry partners to advance valuable gene and cell therapy products to the market.

Our CART-T development and bioprocessing deal with Novartis for CTL019 is a strong endorsement of our expertise and our ability to deliver on complex development and manufacturing opportunities. In April 2016, Novartis expanded this agreement to a second undisclosed target.

Our Opportunities
We are recruiting throughout the Company to support this rapid growth. The positions will be spread across our bioprocessing facility in Cowley, and at our two new sites, Windrush Court in Cowley and a smaller additional bioprocessing facility in Yarnton.

We offer attractive salaries aimed at attracting the best people with recognised relevant experience. We offer a, generous holiday allowance, private healthcare insurance, life assurance, childcare voucher scheme; health cash benefit plan and a generous company pension scheme.

We also offer our employees opportunities for continuous development, in a friendly working environment that is both challenging and rewarding.

We are looking for highly skilled, committed and flexible team players. If that sounds like you, we’d love to hear from you

To apply please send your CV and cover letter to: hr@oxfordbiomedica.co.uk

Please include in your cover letter the relevant job reference number, your current salary and salary expectation.

Our core values

  • Working Together
  • Openness
  • Delivery
  • Inspiration and Innovation
  • Ambition
  • Ethics, Integrity, Trust and Respect
  • Recognition
  • Margaret Margaret

    Margaret Esapa
    Senior Research Scientist
    and Co-ordinator

    Being part of the collective team involved in the pre-clinical development and eventual initiation of three Phase I/II ocular gene therapy studies has been a fantastic experience. These are the first US studies to directly administer lentiviral-derived vector treatments to patients – it is great to be at the forefront of such pioneering clinical development.

  • Satpal Satpal

    Satpal Griffiths
    Quality Control Manager
    (Senior Microbiologist)

    The LentiVector® platform technology is based on a proprietary manufacturing process developed from scratch by Oxford BioMedica. We combine in-house expertise with significant operational and technical knowledge gained through colleagues' various careers within the large pharmaceutical and biopharmaceutical industries. This integrated team was instrumental in the commissioning process of our proprietary manufacturing facility.


Inspiring collaboration

We are privileged to work alongside global pharmaceutical companies, professors, academic institutions, charitable organisations and industry specialists within our chosen fields of development

Pioneering technology

We see our place as world leaders in gene and cell therapy. Using gene and cell therapy as mainstream treatments is now closer than ever and we are well placed to benefit from the rising interest